Table 2.

Healthcare costs for new initiation of dapagliflozin vs other glucose‐lowering drugs

	Baseline costs (US$)		12‐month costs (US$)					30‐month costs (US$)
	Dapa	oGLD	Dapa	oGLD	Diff.	95%CI	p‐value	Dapa	oGLD	Diff.	95%CI	p‐value
Total healthcare cost	1014	979	4968	5054	−86	−351 to 224	.500	11 807	11 906	−99	−629 to 483	.644
Hospital costs	729	705	3136	3456	−321	−587 to −19	.028	7481	8140	−658	−1169 to −108	.024
CV and diabetes	374	378	1410	1569	−160	−303 to −2	.048	3334	3698	−363	−665 to −61	.008
Heart failure	29	27	101	142	−40	−82 to 1	.064	241	343	−102	−184 to −16	.024
Myocardial infarction	32	29	100	153	−53	−107 to −4	.036	240	324	−85	−173 to 1	.052
Stroke	49	38	121	113	8	−34 to 55	.772	250	257	−7	−83 to 63	.724
Kidney	6	20	55	86	−31	−76 to 32	.260	124	203	−78	−170 to 50	.156
Other	355	327	1726	1887	−161	−333 to 61	.148	4147	4442	−295	−660 to 81	.120
Drugs costs	285	274	1832	1597	235	202 to 272	<.001	4326	3766	559	471 to 648	<.001
Glucose‐lowering drugs	186	176	1422	1161	262	233 to 289	<.001	3323	2725	597	527 to 673	<.001
Dapagliflozin	0	0	648	19	629	621 to 639	<.001	1325	70	1255	1231 to 1281	<.001
DPP‐4i	29	29	103	194	−91	−98 to −84	<.001	244	411	−67	−183 to −149	<.001
GLP‐1RA	48	45	201	422	−221	−241 to −203	<.001	567	954	−387	−435 to −339	<.001
Insulin	87	85	372	434	−62	−79 to −44	<.001	952	1082	−130	−176 to −82	<.001
Other GLD	22	17	99	91	7	3 to 12	<.001	234	208	26	16 to 36	<.001
Other drugs	99	98	410	437	−27	−40 to −12	<.001	1003	1041	−38	−71 to −3	.032

Abbreviations: CV, cardiovascular; dapa, dapagliflozin; DPP‐4i, dipeptidyl‐peptidase‐4 inhibitor; GLP‐1RA, glucagon‐like peptide‐1 receptor agonists; oGLD, other glucose‐lowering drugs; SGLT‐2i, sodium glucose‐cotransporter‐2‐inhibitor.